
CHICAGO: Getz Pharma Malaysia Sdn Bhd, a subsidiary company of Getz Pharma (Private) Ltd of Pakistan, is investing US$45 million (RM145.4 million) in its acquisition of 15 acres (6 hectares) of land for its facility in techpark@enstek, Bandar Enstek Nilai.
In a statement, Getz Pharma said the facilities would undertake the research, development, production and commercialisation of sterile injectables, solid dosage, penicillin and biopharmaceutical products.
The plant will be designed to be compliant with the United States Food and Drug Administration (USFDA), the Medicines and Healthcare Products Regulatory Agency of United Kingdom and other agencies of regulated markets.
techpark@enstek is a 524-acre technological hub development in Bandar Enstek under a joint venture between TH Properties Sdn Bhd, the property arm under Tabung Haji, and the Negri Sembilan State Development Corporation (PKNNS).
Getz Pharma Malaysia’s products are primarily targeted at highly regulated markets such as the US, European Union, Australia, Japan and semi-regulated markets such as Russia. It will also serve the Malaysian and Asean markets.
The company is currently applying for Bionexus status. Getz Pharma Pakistan started operations in 1995 and is a subsidiary of Getz Group of Companies based in the US, with a group turnover of US$1.5 billion.
This article appeared in The Edge Financial Daily, May 6, 2010.